Teva- Pharmaceutical Industries Ltd(TEVA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 65.71 | EPS (ttm) | 0.6 | Insider Own | 4.9% | Shs Outstand | 1.17B | Perf Week | -5.04% |
| Market Cap | 45.92B | Forward P/E | 12.78 | EPS next Y | 51.99% | Insider Trans | -1.69% | Shs Float | 1.11B | Perf Month | -2.01% |
| Enterprise Value | 59.15B | PEG | 2.3 | EPS next Q | 0.72 | Inst Own | 25.64% | Short Float | 2.69% | Perf Quarter | 26.8% |
| Income | 0.71B | P/S | 2.65 | EPS this Y | -30.76% | Inst Trans | 6.06% | Short Ratio | 5.35 | Perf Half Y | 28.62% |
| Sales | 17.34B | P/B | 5.92 | EPS next 5Y | 5.55% | ROA | 1.77% | Short Interest | 29.85M | Perf YTD | 26.27% |
| Book/sh | 6.65 | P/C | 12.56 | EPS past 3/5Y | - | ROE | 9.68% | 52W High | -6.21% ($42.02) | Perf Year | 113.03% |
| Cash/sh | 3.14 | P/FCF | 16.83 | Sales past 3/5Y | 5.12% 0.78% | ROIC | 3.51% | 52W Low | 135.42% ($16.74) | Perf 3Y | 381.78% |
| Dividend Est. | - | EV/EBITDA | 13.9 | EPS Y/Y TTM | 532.66% | Gross Margin | 52.52% | Volatility(W/M) | 2.31% 2.57% | Perf 5Y | 289.04% |
| Dividend TTM | - | EV/Sales | 3.41 | Sales Y/Y TTM | 4.4% | Oper. Margin | 18.83% | ATR (14) | 1.12 | Perf 10Y | -10.43% |
| Dividend Ex-Date | 2017/11/27 | Quick Ratio | 0.67 | EPS Q/Q | -303.54% | Profit Margin | 4.07% | RSI (14) | 46.98 | Recom | 1.38 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.88 | Sales Q/Q | -1.38% | SMA20 | -1.92% ($40.18) | Beta | 0.99 | Target Price | $48.09 |
| Payout | - | Debt/Eq | 2.18 | Earnings | 2026/11/3 | SMA50 | 1.86% ($38.69) | Rel Volume | 1 | Prev Close | $40.21 |
| Employees | 33346 | LT Debt/Eq | 1.6 | EPS/Sales Surpr. | -61.39% 3.02% | SMA200 | 14.93% ($34.29) | Avg Volume(3M) | 5.58M | Price | $39.41 |
| IPO | 1982/2/16 | Option/Short | Yes/Yes | Trades | 20589 | Volume | 5,598,873 | Change | -1.99% |
💊 This US-listed ADR represents a multinational pharmaceutical company that is a leading player in the global generic drugs sector and also operates select innovative and biosimilar drugs. Founded in 1901 in Israel and headquartered in Tel Aviv, the company runs a global generic drug supply chain along with a new drug pipeline spanning various therapeutic areas.
Over the past 1 year, on the higher side
6% below its 1-year high.
Traded about as much as usual. That is 100% of its average volume.
Next earnings report: November 3
8 days to go.
TEVA earns moderately but has a weak balance sheet
Of every $100 in sales, $18.83 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -30.8% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $1,390. Peers typically go for $1,427. Compared with its own 2-year average, it is 29% pricier now.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +289.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 25.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #2 of 83 in the industry
Based on market cap of $46B.
TAK#1 Takeda Pharmaceutical Co ADR $64B PER - 
TEVA#2 Teva- Pharmaceutical Industries Ltd $46B PER 65.7 
HLN#3 Haleon plc ADR $45B PER 21.1 
ZTS#4 Zoetis Inc $33B PER 13.3 
UTHR#5 United Therapeutics Corp $25B PER 21.0 
FAQ
What kind of company is TEVA?
TEVA belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of TEVA?
The market cap of TEVA is approximately $45.9B, ranking 342 within its sector.
What is the P/E ratio of TEVA?
TEVA has a P/E ratio of approximately 65.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for TEVA?
TEVA has recorded a 52-week high of $42.02 and a low of $16.74.
